Article on the Commercialization of a Federated Learning-Based AI Drug Discovery Platform Featured in BioPharmaTrend and AI BRIEF
An article covering the world’s first commercialization of a federated learning-based AI drug discovery platform—developed by Elix and LINC using AI models trained on data from 16 pharmaceutical companies—was featured in BioPharmaTrend and AI BRIEF on July 16, 2025.
▼ BioPharmaTrend (July 16, 2025)
Japan’s Elix Launches AI Drug Discovery Platform Trained on Confidential Pharma Data via Federated Learning
▼ AI BRIEF – Daily AI BRIEF(July 16, 2025)
Elix and LINC Launch AI Drug Discovery Platform with Federated Learning